II. Efficacy
- Graft patency after Coronary Artery Bypass Graft- Internal mammary graft stays patent in >90% for >10 years
- Saphenous vein graft patency is much more tenuous- Year 2: 85% are patent
- Year 5: 75% are patent
- Year 8: 65% are patent
 
 
- References
III. Precautions: PTCA as an alternative for Left Main Disease
- 
                          PTCA with DES may be a reasonable alternative to CABG in moderate coronary disease cases previously limited to CABG (e.g. Left main disease)- For moderate left main disease, PTCA with DES outcomes over 10 years are similar to CABG outcomes
- PTCA is a safe, much less invasive procedure than CABG
- CABG has a higher rate of perioperative Cerebrovascular Accident
 
- Caveats- CABG is associated with decreased Angina
- CABG is associated with a better outcome with severe left main disease or multi-vessel disease
- CABG has better outcomes when repeat revascularization is required
 
- References- Rihal (2012) Mayo POIM Conference, Rochester
 
IV. Indications: Absolute Indications in Stable CAD
- Disabling Angina despite maximal medical therapy given acceptable surgical risk- If atypical Angina, confirm cardiac ischemia is cause of symptoms
 
- Significant proximal LAD stenosis (>70%)
- Significant left main Coronary Artery stenosis
- One to two vessel CAD (without proximal LAD stenosis)- LARGE area of viable Myocardium and
- High risk criteria on noninvasive testing
 
- Two vessel CAD- Significant proximal LAD stenosis and
- Ejection Fraction (EF) <50% or ischemia on noninvasive testing
 
- Three vessel CAD- Especially if Ejection Fraction (EF) <50%
 
V. Indications: Possible Indications in Stable CAD
- One vessel CAD and- Proximal LAD Stenosis
 
- One to two vessel CAD (without proximal LAD stenosis)- MODERATE area of viable Myocardium and
- Ischemia on noninvasive testing
 
VI. Indications: Avoid CABG in these patients (cases in which CABG is NOT recommended)
- Borderline Coronary Artery stenosis (<60%) not involving left main Coronary Artery and negative noninvasive testing
- Insignificant Coronary Artery stenosis (<50%)
- One to two vessel CAD (without proximal LAD stenosis)- SMALL area of viable Myocardium and
- No ischemia on noninvasive testing and
- Mild symptoms unlikely to be ischemia or inadequate medical management trial
 
VII. Complications (based on STS Guidelines from 2008)
- Transfusion required: <50%
- Incomplete revascularization: <20%
- Major morbidity (e.g. CVA): <5%
- Mortality: <2%
VIII. Management: Perioperative Medications and Interventions to reduce readmission rates
- 
                          Aspirin
                          - Dose: 325 mg orally daily for one year, then 81 mg daily
- Start and continue 81 mg daily if comorbid bleeding risks
 
- 
                          Beta Blockers- Start at least several days prior to CABG to reduce Atrial Fibrillation risk
- Titrate Heart Rate to 60 bpm as tolerated
- Preferred agents (best evidence): Metoprolol Succinate, Carvedilol, bisproprolol
- Duration- Continue for 1 month following CABG at a minimum
- Continue for at least 3 years following Myocardial Infarction
- Continue indefinately for Systolic Dysfunction
 
 
- 
                          Statins- High dose Statin (e.g. Atorvastatin 80 mg) for most patients
- Low dose Statin for those cannot tolerate high dose
 
- 
                          Cardiac Rehabilitation
                          - Reduces risk of future Myocardial Infarctions
- Reduces readmission rates and mortality rates
- Reinforces Medication Compliance
 
- Follow-up- Phone follow-up within 2-3 days of CABG discharge
- Office follow-up within 7-14 days of CABG discharge
 
- References- (2015) Presc Lett 22(5): 25
- Kulik (2015) Circulation 131(10):927-64 [PubMed]
 
